DCN and myeloid sarcoma: Given the mounting evidence of these proteins as modulators of inflammation in MS (summarised in Figure 1 and reviewed elsewhere) [16], we conducted a systematic neuropathological characterisation of biglycan, decorin, and prolargin in a large human autopsy cohort of MS cases.